Press Detail

PRESS RELEASE

Search at Biotest - company rejects allegations

- Accusations absolutely incomprehensible for Biotest AG

- Proposal for clarification not accepted by public prosecutor

Dreieich, October 15, 2014. The Frankfurt Public Prosecution Office has once again executed a search at Biotest AG, Dreieich. The search is apparently based on the extension of the public prosecutions' investigation into the company's business with Russia, which the public prosecutors have been investigating since 2011 and which led to a search on May 8, 2012 (see ad hoc notification from Biotest AG of May 8, 2012).

Accusations absolutely incomprehensible for Biotest AG

The same defendants are now being accused of breach of trust, bribery and related tax evasion in the markets Poland, Czech Republic, Slovakia, ex-Yugoslavia and Kazakhstan. As with the business with Russia, Biotest AG strongly rejects the allegations. Internal investigations by Biotest AG have confirmed that the compensation for external service providers, as well as the product prices, were absolutely typical for the market - both in comparison with competitors as well as in an international comparison. The allegation of breach of trust, bribery and tax evasion is thus absolutely incomprehensible for Biotest AG.

Proposal for clarification not accepted by public prosecutor

Biotest AG will support the Public Prosecution Office actively in the clarification of the case. Biotest has made available to the public prosecution numerous documents that clarifies its business with Russia. However, Biotest must also acknowledge that multiple offers by the defendants to personally contribute to clarification and to explain the business processes in order to eliminate any misunderstandings have not been accepted to date.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart